Table 2.

Overview of the most important parameters of each patient in the group with hyperoxaluria.

Patient number	BMI (kg/m2)	Age at oxalate evaluation (months)	Etiologiy of SBS	Urinary oxalate (mmol/mol creatinine)	Creatinine (mg/dl)	eGFR (ml/min/1.73 m2)	Renal pathology	Remaining expected short bowel length (%)
1	14.6	15	NEC	138	0.21	186.91	NC	14
2	14.7	63	Volvulus	123	0.21	126.13	None	37
3	15.8	40	Intestinal atresia	115	0.22	132.51	None	32
4	14.7	107	NEC	na	6.53	5.26	dPC	26
5	20.3	154	Volvulus	283	0.31	133.80	NL	21
6	16.86	176	NEC	82	0.31	103.79	None	16
7	14.4	44	Volvulus	126	0.32	113.76	None	27
8	18.85	32	Volvulus, Gastroschisis	120	0.36	108.55	None	9
9	15.7	46	Volvulus, NEC	119	0.37	174.13	None	14
10	22.9	194	Volvulus, Gastroschisis	43.8	0.39	na	None	34
11	18.6	33	Volvulus	229	0.54	na	None	24
12	15.9	50	NEC	244	0.66	139.16	None	22
13	11.96	22	Volvulus	156	0.26	162.54	None	21
14	16.5	278	Intestinal scarring stenosis	na	18.5	2.2	dPC	X

NC, nephrocalcinosis; NL, nephrolithiasis; dPC, diffuse parenchymal calcifications.